Loading clinical trials...

Finasteride (MK-0906) and Male Breast Cancer - A Register-Based Nested Case-Control Study (MK-0906-162/2003.021). | Clinical Trials | Clareo Health

COMPLETED

Finasteride (MK-0906) and Male Breast Cancer - A Register-Based Nested Case-Control Study (MK-0906-162/2003.021).

Finasteride and Male Breast Cancer - A Register-Based Nested Case-Control Study in Denmark, Finland, Norway, and Sweden

NCT01703520•Organon and Co

View on ClinicalTrials.gov

Summary

The objective of this study is to investigate the potential association between finasteride (MK-0906) exposure and the development of breast cancer in men residing in Denmark, Sweden, Finland, and Norway from data in national registries. The primary hypothesis of this study is that the previously reported increased incidence of male breast cancer among finasteride users is explained by confounding factors.

Eligibility

Age

35 - No limit years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•Participant's study medical information available in population-based health and medical registries, prescription registries, and mortality registries in Denmark, Finland, Norway, or Sweden within the observation period of 1995 to 2013
•Male with breast cancer with medical information in one of the 4 country-specific registries in this study OR country- and age-matched control men without breast cancer and with medical information in one of the 4 country-specific registries
•Study participant's exposure to finasteride is available

Exclusion Criteria

•For country- and age-matched control men without breast cancer
•Previous cancer diagnosis or treatment for cancer except non-melanoma skin cancer
•Previous prostatectomy
•Finasteride or dutasteride use (dutasteride is a drug in the same class as finasteride) within first 6 months of registration in the prescription registers (new user design).

Key Dates

Start Date

May 1, 2011

Primary Completion Date

November 30, 2017

Completion Date

November 30, 2017

Last Updated

May 10, 2024

Enrollment

575,216

ACTUAL participants

Conditions

Male Breast Cancer

PrefeRences And ChemoTherapy In Breast Cancer patiEnts

NCT06332976

Female Breast Cancer

View study

RECRUITINGNA

Pulsed Electromagnetic Fields for Analgesia Post Mastectomy

NCT06331793

Female Breast CancerPost Operative Pain

View study

NOT_YET_RECRUITINGPHASE2

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 10, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Finasteride (MK-0906) and Male Breast Cancer - A Register-Based Nested Case-Control Study (MK-0906-162/2003.021).

Inclusion Criteria

Exclusion Criteria

PrefeRences And ChemoTherapy In Breast Cancer patiEnts

Pulsed Electromagnetic Fields for Analgesia Post Mastectomy

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer

Place of Comprehensive Geriatric Assessment in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter)

Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer